![](https://www.udayavani.com/wp-content/uploads/2025/02/arrested-PExels-1-415x311.jpg)
![](https://www.udayavani.com/wp-content/uploads/2025/02/arrested-PExels-1-415x311.jpg)
PTI, Dec 31, 2021, 1:38 PM IST
New Delhi: Serum Institute of India (SII) CEO Adar Poonawala on Friday said it has applied to Indian authorities for full market authorisation of Covishield, stating supplies of the COVID-19 vaccine have exceeded 125 crore doses.
SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government, which had in January this year granted emergency use authorisation in the country.
”Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission,” Poonawala said in a tweet tagging the Central Drugs Standard Control Organisation (CDSCO) and Ministry of Health and Family Welfare.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Air pollution, extreme weather could increase risk of prolonged pregnancy: Study
Carbohydrate cravings may be related to overall severity of depression: Study
SAHAYOGA: Comprehensive care for children with Type 1 Diabetes launched at MAHE Manipal
Newer Advances in Blood Cancer Treatment
Death rates in young adults remain higher post-pandemic, US study finds
Two held in Rs 850 crore ponzi scheme case: Cyberabad Police
Delhi stampede: Opposition blames govt for ‘gross mismanagement’, demands Vaishnaw’s resignation
Passengers got confused between ‘Prayagraj Express, Prayagraj Special’, causing stampede: Sources
2nd US flight in Amritsar, many deportees complain being shackled; third plane on Sunday night
IPL 2025 schedule announced: Opening match between KKR and RCB on March 22
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.